- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
First Helium
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Mesa Laboratories (NASDAQ:MLAB) reported its results for the third quarter ended December 31, 2017. As quoted in the press release: Revenues for the third quarter decreased one percent to $23,671,000 as compared to $23,843,000 for the same quarter last year. Operating (loss) income for the third quarter decreased 330 percent to $(10,088,000) as compared to …
Mesa Laboratories (NASDAQ:MLAB) reported its results for the third quarter ended December 31, 2017.
As quoted in the press release:
Revenues for the third quarter decreased one percent to $23,671,000 as compared to $23,843,000 for the same quarter last year. Operating (loss) income for the third quarter decreased 330 percent to $(10,088,000) as compared to $4,386,000 for the same quarter last year. Net (loss) income for the third quarter was $(11,086,000) or $(2.93) per diluted share of common stock as compared to $3,252,000 or $0.84 per diluted share of common stock for the same quarter last year.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.